Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 3201 (104th)

Medical Device Reform Act of 1996

openUnited States· United States Congress· EN

Introduced

29 March 1996

Last action

2 May 1996 · Committee

Status

Subcommittee Hearings Held.

Sponsors

Rep. Barton, Joe [R-TX-6], Rep. Greenwood, James C. [R-PA-8], Rep. Richardson, Bill [D-NM-3], Rep. Bilirakis, Michael [R-FL-9], Rep. Hall, Ralph M. [R-TX-4], Rep. Gordon, Bart [D-TN-6], Sen. Burr, Richard [R-NC], Rep. Eshoo, Anna G. [D-CA-18], Sen. Coburn, Tom [R-OK], Rep. Brewster, Bill K. [D-OK-3], Rep. Klug, Scott L. [R-WI-2], Rep. Dooley, Calvin M. [D-CA-20], Rep. Ganske, Greg [R-IA-4], Rep. McHale, Paul [D-PA-15], Rep. Bilbray, Brian P. [R-CA-50], Rep. Payne, Lewis F., Jr. [D-VA-5], Rep. Oxley, Michael G. [R-OH-4], Rep. Holden, Tim [D-PA-17], Rep. Fields, Jack [R-TX-8], Rep. Paxon, Bill [R-NY-27], Rep. Schaefer, Dan [R-CO-6], Rep. Tauzin, W. J. (Billy) [R-LA-3], Rep. Fox, Jon D. [R-PA-13], Rep. Upton, Fred [R-MI-6], Rep. Campbell, Tom [R-CA-15], Rep. McIntosh, David M. [R-IN-2], Rep. Cox, Christopher [R-CA-48], Rep. Dreier, David [R-CA-26], Rep. Heineman, Frederick K. (Fred) [R-NC-4], Rep. Funderburk, David [R-NC-2], Rep. Weldon, Dave [R-FL-15], Rep. Hostettler, John N. [R-IN-8], Rep. Shays, Christopher [R-CT-4], Rep. Hastert, J. Dennis [R-IL-14], Rep. Norwood, Charles W. [R-GA-9], Rep. Burton, Dan [R-IN-5], Del. Frazer, Victor O. [I-VI-At Large], Rep. Stearns, Cliff [R-FL-6], Rep. Frisa, Dan [R-NY-4], Rep. Ramstad, Jim [R-MN-3], Rep. Martini, William J. [R-NJ-8], Rep. Dunn, Jennifer [R-WA-8], Rep. Rose, Charlie [D-NC-7], Rep. Myers, John T. [R-IN-7], Rep. Geren, Pete [D-TX-12], Rep. Moorhead, Carlos J. [R-CA-22], Rep. Rohrabacher, Dana [R-CA-48], Rep. Largent, Steve [R-OK-1]

Subjects

Healthcare, Environment

Source updated

3 June 2026

Healthcare · Environment

Summary

Medical Device Reform Act of 1996 - Amends the Federal Food, Drug, and Cosmetic Act (FDCA) to set forth the Food and Drug Administration (FDA) mission. (Sec. 3) Allows device approval applicants to declare a review impasse and mandates use of a dispute resolution process. (Sec. 4) Revises requirements regarding: (1) investigational devise exemptions; (2) premarket approval requirements (mandating a device review priority); (3) humanitarian device exceptions; (4) safety and effectiveness performance standards (allowing consensus standards recognition); (5) effectiveness determinations (as used in classifying devices); (6) premarket notification; (7) classification panels; and (8) premarket approval application review (allowing review by accredited persons). (Sec. 12) Mandates procedures for accrediting parties that review premarket approval applications and conduct good manufacturing practice inspections. (Sec. 13) Mandates reclassification of certain devices. (Sec. 14) Modifies requirements regarding: (1) device tracking; (2) postmarket surveillance; and (3) good manufacturing practice regulations (including foreign harmonization) and inspections (including adding references to accredited entities and post-inspection procedural requirements). (Sec. 18) Regulates the effect of the dissemination of medical texts, peer-reviewed scientific publications, displays at trade shows, and other material. (Sec. 19) Removes distributors from record keeping and reporting requirements. Declares that the failure of a device to perform as labeled or in an acceptable manner does not constitute a malfunction when caused by improper servicing. Repeals user reporting requirements. (Sec. 20) Prohibits subjecting a person to penalties if the person acted in good faith and had no reason to believe the acts violated the law. (Sec. 21) Allows using monetary penalties for violation correction. Entitles violators to reasonable discovery. (Sec. 22) Mandates an information system to track the status of each submission requesting FDA action. (Sec. 23) Prohibits actions by the Secretary of Health and Human Services under the FDCA from requiring the preparation of an environmental impact statement or assessment. (Sec. 24) Prohibits the Secretary from relying on any statements not promulgated in accordance with rulemaking requirements to require any action under the FDCA. (Sec. 25) Mandates training programs for FDA employees regarding FDCA regulations and policies. Allows the FDA to conduct or contract for scientific research only if directly related to FDCA implementation. (Sec. 26) Regulates communications to non-FDA persons regarding certain matters before completion of related investigations.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 29 March 1996

    Introduced

    Referred to the House Committee on Commerce.

    Source: IntroReferral

  2. 29 March 1996

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 29 March 1996

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 15 April 1996

    Referred

    Referred to the Subcommittee on Health and Environment.

    Source: Committee

  5. 1 May 1996

    Committee

    Subcommittee Hearings Held.

    Source: Committee

  6. 2 May 1996

    Committee

    Subcommittee Hearings Held.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 29 March 1996

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 29 March 1996

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 29 March 1996

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 164 sponsors and actors.

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.